Robert Lechleider
Net worth: 2 M $ as of 2026-09-29
Net worth: 2 M $ as of 2026-09-29
Robert Lechleider is currently Chief Medical Officer at Immunome, Inc. since 2023.
Formerly, Dr. Lechleider was Chief Medical Officer at OncoResponse, Inc. from 2020 to 2023 and Senior Vice President-Clinical Development at Seagen, Inc. from 2016 to 2020.
Education includes undergraduate studies at Princeton University and a doctorate from the University of Illinois College of Medicine.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
IMMUNOME, INC. 0.06% | 2026-07-22 | 69,805 ( 0.06% ) | 2 M $ | 2026-09-29 |
| Companies | Position | Start |
|---|---|---|
| IMMUNOME, INC. | Chief Tech/Sci/R&D Officer | 2023-10-18 |
| Companies | Position | End |
|---|---|---|
OncoResponse, Inc.
OncoResponse, Inc. Pharmaceuticals: MajorHealth Technology Discovers cancer immunotherapies by interrogating the human immune system | Chief Tech/Sci/R&D Officer | 2023-09-30 |
| SEAGEN INC. | Chief Tech/Sci/R&D Officer | 2020-03-31 |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 5 |
|---|---|
Seagen, Inc.
Seagen, Inc. Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes cancer medicines | Health Technology |
Immunome, Inc.
Immunome, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company which discovers, develops and commercializes antibody therapeutics | Health Technology |
Princeton University
Princeton University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Illinois College of Medicine
University of Illinois College of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
OncoResponse, Inc.
OncoResponse, Inc. Pharmaceuticals: MajorHealth Technology Discovers cancer immunotherapies by interrogating the human immune system | Health Technology |
Select your edition
All financial news and data tailored to specific country editions